{"id":1011545,"date":"2026-10-19T16:21:36","date_gmt":"2026-10-19T20:21:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\/"},"modified":"2026-10-19T16:21:36","modified_gmt":"2026-10-19T20:21:36","slug":"pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\/","title":{"rendered":"Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Features FORTIFY, the ongoing Phase 1b indication expansion trial of PLN-101095 <\/em><br \/>\n        <em>enrolling patients with ICI-refractory solid tumors<\/em>\n      <\/p>\n<p>SOUTH SAN FRANCISCO, Calif., Oct.  19, 2026  (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain from October 23-27, 2026.\u00a0<\/p>\n<p>\n        <strong>Poster Presentation<\/strong>\n      <\/p>\n<p>\n        <strong>Title:<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PuDfO-bnJx_3KJkXQdlaPkUohXxzEVFn-mJDQ-Mr24vdZ-k1VLoaxCrICyFhE8bqK9X-qEOTmjLHysl20vZSNBoxCy2NPKsNmn5aRoVC4-hfpt4P71gV0-mEXYstBT373nKvvIUsLxS3lLYxexz3-Ygjqx_3XJNUy5RopJjFaBvtRY6JGl9AXULbU6ax4eAUgsZV1SLj1qQvu82GAFjsRfjsCDoTVRkAhxiUf_VhTTP3nwBO11UHPo6DBf4u0GGoRqnpopqkdDGGR86fNoC2oyyusCrg3iaFjEDXS5kEPv4Lkgxg3CrN0_6x-G2DdpONHf1zVFpqE8yHriAwoRKj5VnlHdIdh_fGq53EDijOsFu1n9qZ4SVJtgRFC1axMfxowsRvCp7Vux42CMVas8Ilnw8IyX6Kxlq2JVE7Td4nK4w=\" rel=\"nofollow\" target=\"_blank\">Part 2 Cohort Expansion of a Phase I Study of PLN-101095, a Dual \u03b1v\u03b28\/\u03b1v\u03b21 Integrin Inhibitor, in Combination with Pembrolizumab in Immune Checkpoint Inhibitor\u2013Refractory Advanced Solid Tumours<\/a>\n      <\/p>\n<p>\n        <strong>Presenter: <\/strong>Timothy A. Yap, MBBS, Ph.D., University of Texas, M.D. Anderson Cancer Center<br \/><strong>Session: <\/strong>Development Therapeutics\u00a0<br \/><strong>Date and Time<\/strong>: Friday, October 23, 2026, 3:15 &#8211; 4:00 p.m. CEST<br \/><strong>Location:<\/strong> Hall 5, Poster 1082TiP<\/p>\n<p>\n        <strong>FORTIFY &#8211; PLN-101095 Phase 1b Indication Expansion Trial<\/strong>\n      <\/p>\n<p>PLN-101095 is currently being evaluated in Phase 1a\/1b open-label, dose-escalation and indication expansion trial (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z-zDFXTzj9rhgCBFtEN_0Xh8Xq7MGoHNt74P8jlccwYH31Oh4a9Por8hB6AfXAQWXOoUFylzoknAeSkb2C4NHmzJkezpljrkXR1XPJ3Fiiylgj7wTR_tPOzaQJ-Ifw6A1R1olaDaVm9XZl8yNQPAXI2N2dFgn1qFKhWLr_ZD8LxnvN9OiMb8Jeda9-vUXs-59Rtk1r-td1G7GoSZzP2EtbjKsMGN-vqY6eKNWD3PqFeZCJHIEnxUAwD4cRaSqyvwm2-y766fEYep2-746KLcBx6EwrwIyfCyOPTb9Ak189M=\" rel=\"nofollow\" target=\"_blank\">NCT06270706<\/a>) to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095 when administered orally in combination with\u00a0pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. Pliant is currently enrolling patients in FORTIFY, a Phase 1b open-label, indication expansion trial enrolling three cohorts of patients with non-small cell lung cancer (NSCLC), tumors with high tumor mutational burden or clear cell renal cell carcinoma. Patients will be treated for 14 days with PLN-101095 dosed at 1,000 mg twice daily as monotherapy, after which pembrolizumab will be added as combination therapy.<\/p>\n<p>\n        <strong>About Pliant Therapeutics, Inc.<\/strong>\n      <\/p>\n<p>Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. Pliant\u2019s lead program is PLN-101095, a small molecule, dual-selective inhibitor of \u03b1v\u00df8 and \u03b1v\u00df1 integrins, that is being developed for the treatment of ICI-refractory advanced or metastatic solid tumors. PLN-101095 is being investigated in FORTIFY, a Phase 1b indication expansion trial enrolling patients with NSCLC, tumors with high tumor mutational burden or clear cell renal cell carcinoma. Pliant\u2019s preclinical research is focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules with programs focused on delivering siRNAs to skeletal muscle cells, adipocytes, and renal cells. For additional information, please visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vXFvdVXv-in5Llg2W32ZakZBa0AKHfjhyDnTtcUvfX8aop5ayzZHWLiLrLqjmIJVKLHnzHWEx-lqOye1-7kQUQNFRqcx9vT-lW3pA7x2bOH2KX6RMvuQQuqrBaLPWLaPx0m-5I-5QGv6qE9UoHhhKp7APxicFl1HGm-uj33AkH-U3XpfVO1UXtuOmBnaBrQ0TKViSwcSiSDqF6vAHhBHLcXokFov3KGQ-yqKO55P4rONdlryxnaQIWfGlhgW2zoWGUYAgOuYulp3n-Up05elCSTo3I_dzP8nStsb6l9HJQRO6RQl6qjGedUZs1NX1YOHbb6hqC3UKlEvSFHFVusHSo6kElVLyeAGTOl7QifBh5GJiqTwydSfepcA8HyHLFemUgjm4a14zWtXQUNt9Z-ua2s8rsgLPa6K6FCVUiRvaymNsaxH2c2qKfS1EiV0FLZasimDVO3QIYwjui1lKloYRp7CFFQ_XHhqt6phjPPgt7LlvqUoGJdHzA9hHQfRRxMm8nJIROegV1PgCWsYFRzZ6rzNqoiCGPFd5VU7IW0kxh-HoUYwCV8mWy72wLDJ3GKoPSFgZDvuEF6wg8m-7Pn6dhMpIf8RjZwEOy3dR0C1wCvJzriXrMu-PksNce4k-YnQk480sv--XgCFnw6_qTdkyTANDN6AHSHqh_M5JMnv8ksTZGRITNZkd7oYvamL96ao6s5zFnYUd5WVHTcAcPcsyw==\" rel=\"nofollow\" target=\"_blank\">www.PliantRx.com<\/a>. Follow Pliant on social media at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nOjZWJUugjMPvaPmoNsJjHgvuVg4GtRwmmw8OX6dU8-CBTbXfwPxguQj3dbkRZDOWvy-j5VbLSTuq-GBmYqFfWhl4TSQUpeJFnzdZO4XkzBL0NhlGwg_5ohYUUcMM_Mh1qBk50iVNv2RrrYR4eMdlflFhfrMekZBdoii9__arTjL9KKFcHX84z7DmdeaffeKgqlwxG5Hv0Cdo8FWtzLaWXqIlXhFHO3Os4becUeQe3QoRS1i7_pqomF30jS-sG39p9uoBsSk80kG5DAXPL4NVjKpqgXbVOKZYRAmjVNHrSr1lpguMo6XSH_YKou0pwl6yxEsEbbRFtndokweA5dSN6LSOs4Mz9RCa7Mt0XI3kheNYRAhWfqZ7g68PT81UK7E-78lBPPseVdvNoYL4jPlU67P7mPJe9cZGXNYRRiujJFrAC8_VHcOtoDY2mAOaCGInJhcI8anBd_79PREc-r1sq8A9gZOD6yOIYC_B-X6VFuHnu5m4QXEnvtuURVNK9oAQw_EkgMcEzHhnjFiMONgno758Rjr5_p2sMbPWJLWwvJsGWLfAeb1mUSvc5V4kh4JNXceJAQw6JiNQblEQKt5I4b6TCVJZuybtlB06Nx7zIc=\" rel=\"nofollow\" target=\"_blank\">X<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EvkaqKu3SDkjpxn8cLoIXwY_uy9UpFEUCmnJ-XFl-qhCdHlPeZK9Mhl2Q3SZXrLi7CSNmAUkRuHTr5_HveX747LStJXlSIzCFxz8tub-mMPyWxbOI22pSE0AAqfg_F8ZJIcUvRqfId0i9nIU89ZVOjhUvTEUKQG1wGbWYWm4_tDGz1y_58g8Cp5CDXnFEIjU1HRtNBOGyEmvJhNup9JlXIOSySBcAt9WusvPGSSgKAtbp1rCrIYx7TrihYwuQVJyCSPhdRe7L_T9kWVk1fPVxFt1xiCEIp9YDg3TLXOgLjlobNy-wi0MCH0haFiVqhFN2mwBrQH6EXHM4OXt9emOfeuczAWcatfpN0ps-1MSt0LzOUnvsn0kfZgv3rmmh8Q-FnhkDJqLR0Ru1Rj0s14sQILNbK9BJTOoA2-UIrKOl3rthKdiqWn9LAAh25pgXsXB9KuNuTURoBGuK7nAOXvWBudOLdQ_CQMBfKZ9sAPXoPSWyryEMtU9VRaoF16xv2U1Mqlb3_Jo54GOxH2B0UDcgDfvKy0sbaAy8Pg1Vq4anajLZGC-XFDUzQP_akdZcw_8YenCxwpmk2zN_FHqzLY8A1DZDaQMnPACAjZ3Es5KacksKsUZOsN20K7L5WpV_ZfhiVgkJetKJ7bdd5-HppUC2GeRXdiUmMPfgvRqv7pBE5NlZA3syq7J6_VhcDmcU4AE\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CMCPVj8oUMpSPXVEguyxeV67vXYNoJAHrgZPQn7gBTUC679Rg6actGNW5QspciqD71A6gBVOfCdaqXdy6piW0BJqdLvir1YCzLOX-O4wpPnQcXfGK1kNqI4OdTDZHzyYR0wOZB4TdOZmxi5_PveJ_F0r0_fyMHcvyPOgoIi0bGbpnkcjVr1iTL4V3DlOPJAUi7RFedJbveW8TZSx7SzNKzPsapN84yWdM2GjaozRfVx98frXS9wncfEOhMX5xTIDsCAQyLnSPVWl30svTiqlsee6MwOi3v0meV4pnc5IO59BmxI1MghI0hIiH8YixLKhlr2RRA49A21g-R03zeTFhin9_blgYgVz5MO4OEOEx6ihIK8GnG8g3xaXB1Q4V2rhEkw5RL2OtwcUFDgYR-aQjPDhpj_KsHNu6JyoHlH8BnyLoUUKzYerhzdOtJ6loPOgPTvSYg-G_2UCkrKDgH4uusB_f-zaRcbYPjHU5qiwvErJ0HpQHO1YEV-wCEjZgG1rC1xjhIZc518w8GjFALZNdhE4FhA6jwJW6JcJcFFJrzxEfzPamwtWQI9tACRfLXRgzrMepkEfzceQVDSHQ79D6T4adOQVFbLwSVzVybg_4RVb4yzudy6ScK0Z32J1flG14bPv35nG_pTG6HzACfijdTQYxtoKo_UdnXm2CI56l6lfMH50YEGylZnZmofDkQbA\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p>\n        <strong>Investor and Media Contact:<\/strong><br \/>\n        <br \/>Christopher Keenan<br \/>Vice President, Investor Relations and Corporate Communications<br \/>Pliant Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=f8fMJ3mGhH-XW4EXax5yeIa5tOYXYfeqpAI1kyDtSMmQ8XYGixVUT-7Vtrv_cR_-SRFndhaBO1ssCnng5MDaVS2IwrrDhczK19SHy90CjvQ=\" rel=\"nofollow\" target=\"_blank\">ir@pliantrx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0ODUwOSM3OTAzMzE4IzIxODU0NzY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjY0NTAxNTctZmE4ZC00YzIwLTkxMzQtZDk3NmVjNzM0ZDQ3LTExOTcwMzAtMjAyNi0xMC0xOS1lbg==\/tiny\/Pliant-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Features FORTIFY, the ongoing Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain from October 23-27, 2026.\u00a0 Poster Presentation Title: Part 2 Cohort Expansion of a Phase I Study of PLN-101095, a Dual \u03b1v\u03b28\/\u03b1v\u03b21 Integrin Inhibitor, in Combination with Pembrolizumab in Immune Checkpoint Inhibitor\u2013Refractory Advanced Solid Tumours Presenter: Timothy A. Yap, MBBS, Ph.D., University of Texas, M.D. Anderson Cancer CenterSession: Development Therapeutics\u00a0Date and Time: Friday, October 23, 2026, 3:15 &#8211; 4:00 p.m. CESTLocation: Hall 5, Poster 1082TiP FORTIFY &#8211; PLN-101095 Phase &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1011545","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Features FORTIFY, the ongoing Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain from October 23-27, 2026.\u00a0 Poster Presentation Title: Part 2 Cohort Expansion of a Phase I Study of PLN-101095, a Dual \u03b1v\u03b28\/\u03b1v\u03b21 Integrin Inhibitor, in Combination with Pembrolizumab in Immune Checkpoint Inhibitor\u2013Refractory Advanced Solid Tumours Presenter: Timothy A. Yap, MBBS, Ph.D., University of Texas, M.D. Anderson Cancer CenterSession: Development Therapeutics\u00a0Date and Time: Friday, October 23, 2026, 3:15 &#8211; 4:00 p.m. CESTLocation: Hall 5, Poster 1082TiP FORTIFY &#8211; PLN-101095 Phase &hellip; Continue reading &quot;Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-19T20:21:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0ODUwOSM3OTAzMzE4IzIxODU0NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026\",\"datePublished\":\"2026-10-19T20:21:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\\\/\"},\"wordCount\":390,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0ODUwOSM3OTAzMzE4IzIxODU0NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\\\/\",\"name\":\"Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0ODUwOSM3OTAzMzE4IzIxODU0NzY=\",\"datePublished\":\"2026-10-19T20:21:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0ODUwOSM3OTAzMzE4IzIxODU0NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0ODUwOSM3OTAzMzE4IzIxODU0NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\/","og_locale":"en_US","og_type":"article","og_title":"Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026 - Market Newsdesk","og_description":"Features FORTIFY, the ongoing Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain from October 23-27, 2026.\u00a0 Poster Presentation Title: Part 2 Cohort Expansion of a Phase I Study of PLN-101095, a Dual \u03b1v\u03b28\/\u03b1v\u03b21 Integrin Inhibitor, in Combination with Pembrolizumab in Immune Checkpoint Inhibitor\u2013Refractory Advanced Solid Tumours Presenter: Timothy A. Yap, MBBS, Ph.D., University of Texas, M.D. Anderson Cancer CenterSession: Development Therapeutics\u00a0Date and Time: Friday, October 23, 2026, 3:15 &#8211; 4:00 p.m. CESTLocation: Hall 5, Poster 1082TiP FORTIFY &#8211; PLN-101095 Phase &hellip; Continue reading \"Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-19T20:21:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0ODUwOSM3OTAzMzE4IzIxODU0NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026","datePublished":"2026-10-19T20:21:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\/"},"wordCount":390,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0ODUwOSM3OTAzMzE4IzIxODU0NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\/","name":"Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0ODUwOSM3OTAzMzE4IzIxODU0NzY=","datePublished":"2026-10-19T20:21:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0ODUwOSM3OTAzMzE4IzIxODU0NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0ODUwOSM3OTAzMzE4IzIxODU0NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-european-society-for-medical-oncology-congress-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1011545","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1011545"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1011545\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1011545"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1011545"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1011545"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}